Congress Reports

ENETS 2024 – Vienna, Austria

The Highlights of ENETS 2024 Congress Report is now available as a free, downloadable resource for healthcare professionals.

Together with the world-renowned neuroendocrine (NET) experts Wouter de Herder (endocrinologist) and Jaume Capdevila (oncologist), the most important presentations and posters on genetics, epigenetics & biomarker testing, the treatment of neuroendocrine neoplasms, imaging, clinical trials, and patient support have been summarized to keep you up to date with the latest science on the management of NET. 

EANM 2023 – Vienna, Austria

The 36^th annual congress of the European Association of Nuclear Medicine (EANM) held in Vienna, Austria, and virtually from the 9^th -13^th of September brought more than 7,600 leading experts from across the globe together to discuss the groundbreaking updates and scientific advancements in nuclear medicine. This memo inOncology special issue focuses on innovative approaches in neuroendocrine tumors (NETs), such as using SSTR-antagonists as diagnostic agents, combining radioligand therapy with standard treatments, personalizing PRRT-regime and data from alpha-emitting radiopharmaceuticals. Within the realm of prostate cancer, the report also discusses advances in PSMA-based treatment in metastatic castration-resistant prostate cancer and the benefits of PET imaging, covering the results from the VISION and the LuTectomy trials.

Click here to learn more.

EANM 2022 – Barcelona, Spain

At the EANM congress held in Barcelona, Spain, and virtually from 15^th – 19^th October 2022, practice-changing data and high-quality education attracted more than 7,000 participants from over 121 countries. This memo inOncology special issue provides an insight into novel radio diagnostic tracers for PET imaging as well as biomarkers for prostate cancer. Moreover, patient reported outcomes, quality of life data and radioligand therapy for mCRPC with alpha emitters are summarized. The second part of this report deals with neuroendocrine tumor (NET) imaging updates including for example promising fluorine-18 labeled somatostatin analogues. As an add-on you can find data on the efficacy and safety of ¹⁷⁷Lu-DOTATATE in pancreatic and midgut NETs as well as retrospective data of ²²⁵Ac-DOTATOC in the upfront as well as salvage treatment setting in patients with NETs.

Click here to learn more.

NANETS 2022 – Washington, USA

At the NANETS congress held in Washington, United States, and virtually from 27^th – 29^th October 2022, new therapeutic options were presented and the future of neuroendocrine tumor (NET) research discussed. The meeting made this year’s tagline “educating medical and professional researchers in the diagnosis and treatment of NET disease and supporting research and innovation in the field” more than just a slogan, thus, this memo inOncology report provides a comprehensive overview of three of the most actively investigated areas in the field: advances in peptide receptor radionuclide therapy, potential applications of “passive” and “active” immunotherapy and novel biomarkers.

Click here to learn more.